Altimmune (NASDAQ:ALT) Stock Price Up 9.9%

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) traded up 9.9% on Wednesday . The company traded as high as $7.20 and last traded at $7.20. 2,009,333 shares traded hands during trading, a decline of 62% from the average session volume of 5,243,963 shares. The stock had previously closed at $6.55.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. The Goldman Sachs Group assumed coverage on shares of Altimmune in a research note on Wednesday, January 24th. They set a "neutral" rating and a $13.00 price objective on the stock. Guggenheim lowered Altimmune from a "buy" rating to a "neutral" rating in a report on Monday. HC Wainwright lowered their target price on Altimmune from $15.00 to $12.00 and set a "buy" rating on the stock in a report on Monday, April 1st. Finally, B. Riley reaffirmed a "buy" rating and set a $20.00 target price on shares of Altimmune in a report on Thursday, March 28th.

Altimmune Stock Performance

The company has a 50 day simple moving average of $9.20 and a two-hundred day simple moving average of $7.64. The company has a market cap of $501.19 million, a PE ratio of -4.28 and a beta of 0.05.

Altimmune (NASDAQ:ALT - Get Free Report) last released its earnings results on Wednesday, March 27th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.02. Altimmune had a negative return on equity of 44.77% and a negative net margin of 20,780.75%. The company had revenue of $0.04 million for the quarter. As a group, analysts expect that Altimmune, Inc. will post -1.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Altimmune

Several institutional investors have recently made changes to their positions in the company. Timelo Investment Management Inc. lifted its holdings in Altimmune by 2,597.0% in the 4th quarter. Timelo Investment Management Inc. now owns 809,095 shares of the company's stock worth $9,102,000 after purchasing an additional 779,095 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in Altimmune by 153.1% in the 3rd quarter. GSA Capital Partners LLP now owns 445,868 shares of the company's stock worth $1,159,000 after purchasing an additional 269,676 shares during the last quarter. Lighthouse Investment Partners LLC acquired a new stake in Altimmune in the 4th quarter worth approximately $4,493,000. Gerber LLC lifted its holdings in Altimmune by 10.2% in the 1st quarter. Gerber LLC now owns 281,778 shares of the company's stock worth $2,868,000 after purchasing an additional 26,000 shares during the last quarter. Finally, Dark Forest Capital Management LP lifted its holdings in Altimmune by 13.4% in the 3rd quarter. Dark Forest Capital Management LP now owns 230,353 shares of the company's stock worth $599,000 after purchasing an additional 27,210 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.